Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 80%-85% of lung cancer cases.³ Your doctor may talk to you about the type and stage of your disease, using numbers that show the level of severity and if it has spread. For example, stage 0 lung cancer is less severe and localized, and stage IV is more severe and has spread. There can be different treatments for lung cancer depending on the type and stage, so knowing the stage can help guide your doctor’s treatment choices.⁴

A biomarker is a code in your tumor that contains important information which can help your doctor understand what’s causing your tumor to grow and spread. KRAS G12C is a type of biomarker in NSCLC.⁵

KRAS is a protein we all have in our bodies that works like an on/off switch, telling our cells when to grow and when to stop growing. Sometimes this protein can mutate (change). KRAS G12C is one of these mutations, and it makes the on/off switch get stuck in the “on” position. This causes cells to multiply uncontrollably and grow into tumors.^6-8

Laboratories can analyze a tissue sample of your tumor (from a biopsy) or in some cases your blood to test for any biomarkers it may have. Biomarkers can provide information about your type of cancer. There are two kinds of biomarker tests that your doctor can order. Next Generation Sequencing is a test that looks for many different kinds of biomarkers at a time. Single Gene Testing is used by doctors to look for just one biomarker at a time.⁹ Getting tested will show if you’re among the 1 in 8 people with NSCLC who have the KRAS G12C biomarker.¹ With this information in hand, your doctor can tailor your treatment plan.² Ask your doctor which test may be right for you.

Biomarker Assist is comprised of two programs, the Next Generation Sequencing (NGS) Affordability Program and the KRAS Single Gene Test (SGT) Program. Please refer to subsequent questions for more details on each program. Programs valid for testing performed through December 31, 2023.

The Biomarker Assist NGS Affordability Program may help eligible, commercially insured patients lower out-of-pocket costs for their NGS biomarker test, including deductible, co-insurance, and co-payment. Eligible patients may pay as little as $0 out-of-pocket for their NGS biomarker test, up to the program maximum of $1000.^† There is no income requirement for the Biomarker Assist NGS Affordability Program.

This is a summary; please see full terms and conditions for program requirements and limitations.

The Biomarker Assist KRAS Single Gene Test Program is a voucher program to cover the costs of the KRAS Single Gene Test prescribed by your doctor. All you need to do is ask your doctor if this test is right for you.

This is a summary; please see full terms and conditions for program requirements and limitations.

The Biomarker Assist NGS Affordability Program is available for eligible, commercially insured patients with stage IV metastatic non-small cell lung cancer (NSCLC) with NGS biomarker test coverage (this program covers eligible patient's out-of-pocket obligations after insurance coverage).

The Biomarker Assist KRAS Single Gene Test Program is available for any patient with stage IV metastatic non-small cell lung cancer regardless of insurance type or status.

Eligible patients may pay as little as $0 out-of-pocket for the NGS biomarker test, up to the program maximum of $1000.^†

• If you have paid your out-of-pocket responsibility to the lab, you will need to complete the enrollment, provide patient authorization, and send in your Explanation of Benefits (EOB) form with proof of payment to Biomarker Assist. An EOB is a statement from your health insurance plan describing what costs it will cover for medical care or products you’ve received. The EOB is generated when your provider submits a claim for the services you received. Biomarker Assist will review your enrollment EOB form and proof of payment to confirm eligibility. If eligible, a check will be processed and sent to your address.
• If you have not paid your out-of-pocket responsibility to the lab, you will need to complete the enrollment, provide patient authorization, and send in your EOB form to Biomarker Assist. Biomarker Assist will review your enrollment and EOB form to confirm eligibility. If eligible, a check will be processed and sent to your lab.

If you do not send the EOB form to Biomarker Assist within 180 days of the date of service, you will not be eligible for reimbursement. Test must be completed by December 31, 2023 and last day to submit documentation is June 29, 2024.

If you paid your out-of-pocket to the lab, once the Explanation of Benefits (EOB) and proof of payment are received, and eligibility confirmed, the check if sent by UPS will arrive in 7 business days to the address you provided. If you have not paid your out-of-pocket to the lab, once the EOB are received, and eligibility confirmed, the check if sent by UPS will arrive in 7 business days to the lab.

This is a summary; please see full terms and conditions for program requirements and limitations.